Atypical Femoral Fractures (AFF) from Bone Remodeling Agents in Patients with Cancer

Anti-resorptive drugs like bisphosphonates (BP) and denosumab are widely used for prevention and treatment of skeletal diseases, such as osteoporosis and bone metastases and mainly work through the prevention of osteoclast-mediated bones resorption. BP can lead to atypical femoral fractures (AFF) th...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2018-11, Vol.38 (11), p.6439-6444
Main Authors: Kordoni, Maria, Rigakos, Georgios, Kim, Young Hun Minjoo, Kaklamanis, Loukas, Nikolatou-Galitis, Ourania, Hadjiyassemi, Lina, Labropoulos, Stefanos, Razis, Evangelia
Format: Article
Language:English
Subjects:
Biocompatibility
Biomedical materials
Bisphosphonates
Bone cancer
Bone remodeling
Bone resorption
Bones
Breast cancer
Cancer
Diagnostic systems
Femur
Fractures
Literature reviews
Medical treatment
Metastases
Monoclonal antibodies
Osteoporosis
Patients
Prevention
Quality of life
Targeted cancer therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anti-resorptive drugs like bisphosphonates (BP) and denosumab are widely used for prevention and treatment of skeletal diseases, such as osteoporosis and bone metastases and mainly work through the prevention of osteoclast-mediated bones resorption. BP can lead to atypical femoral fractures (AFF) that is a rare, easily misdiagnosed treatment-related complication with great impact on the quality of life of patients. We present a concise review of the literature on BP related AFF based on the cases of 3 breast cancer patients that reflect the diagnostic pitfall of this rare entity. In conclusion, breast cancer patients very often are exposed to BP use and are at risk of developing AFF.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.13005